TickerGuard
Buy Day today: Neutral (50) Mixed market breadth · major macro event coming up
ELOX

Eloxx Pharmaceuticals, Inc.

13.90$ +1.1% vs. previous close Closing price · As of: Oct 12, 2026
🔔 Watch stock
Add to watchlist

Share this page

LinkedIn WhatsApp Email

Stock Watch

Stock Watch will tell you what changes at Eloxx Pharmaceuticals, Inc..

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 11.00 $ to 21.00 $ · Last price: 13.90 $ (As of: October 12, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.1$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 3m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 27.1%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. -162,178.5

Performance

Perf. 1M ?Price performance over the last month. 13.30%
Perf. 3M ?Price performance over the last 3 months. –
Perf. 6M ?Price performance over the last 6 months. –
YTD Performance (%) ?Price performance since the start of the year (Year to Date). –
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -28.2%
Perf. Since Inception ?Price performance since the first available trading day (06/09/2026) — with a complete history, that is since the IPO. 24.80%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 16.40$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 16.90$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 37.0
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 89.7%

Calculated from the price history · as of 10/10/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. 4.7
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 0.0
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 1.3
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. –
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. 0.1
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. –
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. 0.0%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. 0.0%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? 0.0%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). 0.0%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. very low -225.9%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. –
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. warning zone -84.67
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 1 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. -100.00%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. –
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. –

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. E (23 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2016 · Revenue: 0 $M 2016 · Operating income: -4 $M 2016 · Net income: -8 $M 2017 · Operating income: -20 $M 2017 · Net income: -21 $M 2018 · Operating income: -47 $M 2018 · Net income: -47 $M 2019 · Operating income: -51 $M 2019 · Net income: -51 $M 2020 · Operating income: -29 $M 2020 · Net income: -35 $M 2021 · Operating income: -42 $M 2021 · Net income: -67 $M 2022 · Revenue: 0 $M 2022 · Operating income: -34 $M 2022 · Net income: -36 $M 2023 · Revenue: 0 $M 2023 · Operating income: -17 $M 2023 · Net income: -17 $M 2024 · Revenue: 6 $M 2024 · Operating income: -2 $M 2024 · Net income: -3 $M 2025 · Revenue: 0 $M 2025 · Operating income: -6 $M 2025 · Net income: -6 $M
2016201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 0 -4 -8 -3,580.74 -4 5 9
2017 – -20 -21 -1,875.85 -16 21 25
2018 – -47 -47 -640.07 -31 43 51
2019 – -51 -51 -588.09 -39 36 59
2020 – -29 -35 -379.16 -28 10 26
2021 – -42 -67 -419.65 -35 22 45
2022 0 -34 -36 -183.13 -32 -11 21
2023 0 -17 -17 -72.98 -14 -23 2
2024 6 -2 -3 -9.20 -5 -24 3
2025 0 -6 -6 -5.34 -6 -12 5

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2026: Q1 · 0.0 $M Q1

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2026: Q1 – – 0 – – -6 -6

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 3 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet

Risk & Weakness

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Strong Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings 4
Price Target (average) 38.25$
Distance to price 175.2% The price target sits 175.2% above the current price.

Distribution of Recommendations

Strong Buy 4
Buy 0
Hold 0
Sell 0
Strong Sell 0

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -2.10 -2.85 – -0.99 0 – 3
12/31/2027 -2.72 -3.61 – -1.83 0 – 3

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

AI classification

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.

How the Rating Is Built

Quality check

AAQS

1/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% -100.0%
  • Exp. sales growth 3Y > 5% –
  • EBIT growth 10Y > 5% –
  • Exp. EBIT growth 3Y > 5% –
  • Net debt < 4x EBIT –
  • EBIT positive, 10Y straight 0
  • Max. EBIT decline < 50% –
  • Return on equity > 15% –
  • ROCE > 15% –
  • Expected return > 10% –

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

The company

About the Company

Employees
10
Headquarters
Arlington, MA
Address
P.O. Box 274, 02476 Arlington, United States
Phone
781 577 5300
IPO Date
06/09/2026
Stock Split
1:11 on 06/01/2026
Stock Split
1:40 on 12/02/2022
Stock Split
1:20 on 12/20/2017

Management

Management
Name Title Birth Year
Sumit Aggarwal M.B.A. President, CEO & Director 1973
Daniel E. Geffken M.B.A. Interim Chief Financial Officer 1957
John Woolford VP & Head of Corporate Development –
Ali Hariri M.D. Chief Medical Officer –
Roger Clark VP & Head of Discovery Sciences –
Teji Singh VP & Head of Clinical Development –

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Data as of: October 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?